PD-L1 inhibitors in the pipeline: Promise and progress

Checkpoint inhibitors have improved survival for patients with melanoma, non-small-cell lung cancer (NSCLC), bladder, head and neck and other cancers. Antibodies against PD-L1, including atezolizumab, avelumab and durvalumab, are also being developed and have been approved for various cancers. Compa...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncoimmunology
Glavni autori: Vanella, Vito, Festino, Lucia, Strudel, Martina, Simeone, Ester, Grimaldi, Antonio M., Ascierto, Paolo A.
Format: Artigo
Jezik:Inglês
Izdano: Taylor & Francis 2017
Teme:
Review
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5739559/
https://ncbi.nlm.nih.gov/pubmed/29296516
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2017.1365209
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items